Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,728 GBX | +1.38% | +4.69% | +19.19% |
05-02 | GSK knew about Zantac cancer risk, attorneys tell jury in first trial | RE |
05-02 | GSK : Buy rating from Deutsche Bank | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.19% | 86.83B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- US FDA Restricts Second-line Use Of GSK's Zejula In Ovarian Cancer With BRCA Mutations